Infant Bacterial Therapeutics AB
STO:IBT B
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Infant Bacterial Therapeutics AB
STO:IBT B
|
SE |
|
S
|
Studio Samick Co Ltd
KOSDAQ:415380
|
KR |
|
Hongda High-Tech Holding Co Ltd
SZSE:002144
|
CN |
|
T
|
Triple Point Energy Efficiency Infrastructure Company Plc
LSE:TEEC
|
UK |
|
K
|
Kingsgate Consolidated Ltd
OTC:KSKGF
|
AU |
|
C
|
Chijet Motor Co Inc
NASDAQ:CJET
|
CN |
|
Delivra Health Brands Inc
XTSX:DHB
|
CA |
|
O
|
Openedges Technology Inc
KOSDAQ:394280
|
KR |
|
I
|
Inter Rock Minerals Inc
XTSX:IRO
|
CA |
|
PacificHealth Laboratories Inc
OTC:PHLI
|
US |
|
L
|
Lakes Blue Energy NL
OTC:LKOLF
|
AU |
Bankruptcy Probability
Infant Bacterial Therapeutics AB's probability of bankruptcy is hidden . The solvency score is hidden .
We take all the information about a company's solvency (such as how easily a company can pay interest on its outstanding debt, how much cash it has, the amount of debt, and more) and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Infant Bacterial Therapeutics AB Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SE |
I
|
Infant Bacterial Therapeutics AB
STO:IBT B
|
680.3m SEK |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
900.7B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
581B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
236.9B GBP |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
304.8B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
232.5B CHF |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
156.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Infant Bacterial Therapeutics AB's probability of bankruptcy is hidden .
The probability of bankruptcy is estimated using credit risk models that assess its financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Infant Bacterial Therapeutics AB has no debt.
You can find a full breakdown on its Balance Sheet.
